To support Japan’s transition to a growth-oriented economy, JIC group is committed to strengthening industrial competitiveness while making investments that can have an impact on society. This Includes realizing Society 5.0, creating new businesses and industries through GX and DX that resolve global social challenges, enhancing the international competitiveness of domestic industries, and industry restructuring.
Focuses on direct secondary investments, where private capital remains scarce. By targeting mid- to late-stage startups that have previously been compelled to pursue early exits such as small-scale IPOs, aim to provide a platform that accelerates their growth trajectory and contributes to the emergence of unicorns originating from Japan.
Genesia Venture Fund IV Investment Limited Partnership
Date announced
June 27, 2025
Amount investedAmount of commitment
JPY3.5 billion
Fund summary
Primarily invests in pre-seed/seed-stage startups. Despite being a Japanese VC, has established a strong presence in Southeast Asia by supporting partnerships between Japanese companies and local startups, and has also expanded into India. In Japan, it backs promising startups that leverage digital technology to address industry-specific challenges, with the goal of promoting industrial DX.
mint startup fund II Investment Limited Partnership
Date announced
May 21, 2025
Amount investedAmount of commitment
JPY2 billion
Fund summary
Focuses on pre-seed and seed stage investments to support the real-world application of technologies such as AI and blockchain. Through a free office support program for entrepreneurs during the preparation and start-up stages of their business, provides opportunities for them to participate in the entrepreneurial community and network with experts and well-known business leaders. Also provides support for recruitment of engineers.
Catalys Pacific Phase III Select Fund, LP (Formerly known as Catalys Pacific Post-POC Fund, LP）
Date announced
May 15, 2025
Amount investedAmount of commitment
USD14 million
Fund summary
Invests in drug discovery startups from its existing fund portfolio that are developing drug candidates in Phase 3 clinical trials, and supports late-stage development through to new drug approval and subsequent commercialization.
Provides growth capital to mid- and later-stage startups and supports their development by introducing them to its domestic and international network. Aims to contribute to the diversity of domestic company management by leveraging a track record of investing in women entrepreneurs through existing fund.
Focuses on supporting the cutting-edge drug discovery technologies of academia, research institutes, pharmaceutical companies and other organizations from the startup stage. Primarily invests in Japanese drug discovery seeds to commercialize them. Leverages its overseas investment infrastructure and network to invest in early-stage global drug discovery startups.
Invests in large- and mid-sized listed companies in Japan and develops trusted relationships with the management teams of investee companies to support management initiatives aimed at long-term, sustainable growth and enhanced corporate value. As a major shareholder in investee companies, seeks to encourage them to take healthy risks and invest in growth, adopting a sustainable approach to enhance their corporate value and improving their key performance metrics to foster the development of corporate activities of the large- and medium-sized Japanese companies that drive the Japanese economy, and to create a virtuous cycle for the broader Japanese economy.
Domestic investment and Innovation
Startup
Regional management resources
Business consolidation